Jaspreet Singh Sahota1, Claire Mary Smith1,2, Priya Radhakrishnan2, Craig Winstanley3, Marina Goderdzishvili4, Nina Chanishvili4, Aras Kadioglu3, Chris O'Callaghan1,2, Martha Rebecca Jane Clokie1. 1. 1 Department of Infection, Immunity and Inflammation, University of Leicester , Leicester, United Kingdom . 2. 2 Respiratory, Critical Care, and Anaesthesia, University College London , Institute of Child Health, London, Great Ormond Street Hospital, London, United Kingdom . 3. 3 Department of Clinical Infection Microbiology and Immunology, Institute of Infection and Global Health, University of Liverpool , Liverpool, United Kingdom . 4. 4 Eliava Institute of Bacteriophages , Microbiology, and Virology, Tbilisi, Georgia .
Abstract
BACKGROUND: The rise in antibiotic-resistant Pseudomonas aeruginosa and the considerable difficulty in eradicating it from patients has re-motivated the study of bacteriophages as a therapeutic option. For this to be effective, host range and viability following nebulization need to be assessed. Host-range has not previously been assessed for the Liverpool Epidemic Strain (LES) isolates that are the most common cystic fibrosis-related clone of P. aeruginosa in the UK. Nebulization studies have not previously been linked to clinically relevant phages. METHODS: 84 phenotypically variable isolates of the LES were tested for susceptibility to seven bacteriophages known to have activity against P. aeruginosa. Five of the phages were from the Eliava Institute (IBMV) and 2 were isolated in this study. The viability of the two bacteriophages with the largest host ranges was characterized further to determine their ability to be nebulized and delivered to the lower airways. Phages were nebulized into a cascade impactor and the phage concentration was measured. RESULTS: The bacteriophages tested killed between 66%-98% of the 84 Liverpool Epidemic Strain isolates. Two isolates were multi phage resistant, but were sensitive to most first line anti-Pseudomonal antibiotics. The amount of viable bacteriophages contained in particles that are likely to reach the lower airways (<4.7 μm) was 1% for the Omron and 12% AeroEclipse nebulizer. CONCLUSIONS: Individual P. aeruginosa bacteriophages can lyse up to 98% of 84 phenotypically diverse LES strains. High titers of phages can be effectively nebulized.
BACKGROUND: The rise in antibiotic-resistant Pseudomonas aeruginosa and the considerable difficulty in eradicating it from patients has re-motivated the study of bacteriophages as a therapeutic option. For this to be effective, host range and viability following nebulization need to be assessed. Host-range has not previously been assessed for the Liverpool Epidemic Strain (LES) isolates that are the most common cystic fibrosis-related clone of P. aeruginosa in the UK. Nebulization studies have not previously been linked to clinically relevant phages. METHODS: 84 phenotypically variable isolates of the LES were tested for susceptibility to seven bacteriophages known to have activity against P. aeruginosa. Five of the phages were from the Eliava Institute (IBMV) and 2 were isolated in this study. The viability of the two bacteriophages with the largest host ranges was characterized further to determine their ability to be nebulized and delivered to the lower airways. Phages were nebulized into a cascade impactor and the phage concentration was measured. RESULTS: The bacteriophages tested killed between 66%-98% of the 84 Liverpool Epidemic Strain isolates. Two isolates were multi phage resistant, but were sensitive to most first line anti-Pseudomonal antibiotics. The amount of viable bacteriophages contained in particles that are likely to reach the lower airways (<4.7 μm) was 1% for the Omron and 12% AeroEclipse nebulizer. CONCLUSIONS: Individual P. aeruginosa bacteriophages can lyse up to 98% of 84 phenotypically diverse LES strains. High titers of phages can be effectively nebulized.
Entities:
Keywords:
P. aeruginosa; bacteriophages; cystic fibrosis; nebulization
Authors: Sharon S Y Leung; Thaigarajan Parumasivam; Fiona G Gao; Nicholas B Carrigy; Reinhard Vehring; Warren H Finlay; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Hak-Kim Chan Journal: Pharm Res Date: 2016-02-29 Impact factor: 4.200
Authors: Sharon S Y Leung; Thaigarajan Parumasivam; Fiona G Gao; Elizabeth A Carter; Nicholas B Carrigy; Reinhard Vehring; Warren H Finlay; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Hak-Kim Chan Journal: Int J Pharm Date: 2017-02-03 Impact factor: 5.875
Authors: Nicholas B Carrigy; Rachel Y Chang; Sharon S Y Leung; Melissa Harrison; Zaritza Petrova; Welkin H Pope; Graham F Hatfull; Warwick J Britton; Hak-Kim Chan; Dominic Sauvageau; Warren H Finlay; Reinhard Vehring Journal: Pharm Res Date: 2017-06-23 Impact factor: 4.200
Authors: Sharon S Y Leung; Thaigarajan Parumasivam; An Nguyen; Thomas Gengenbach; Elizabeth A Carter; Nicholas B Carrigy; Hui Wang; Reinhard Vehring; Warren H Finlay; Sandra Morales; Warwick J Britton; Elizabeth Kutter; Hak-Kim Chan Journal: Eur J Pharm Biopharm Date: 2018-02-24 Impact factor: 5.571
Authors: Elaine M Waters; Daniel R Neill; Basak Kaman; Jaspreet S Sahota; Martha R J Clokie; Craig Winstanley; Aras Kadioglu Journal: Thorax Date: 2017-03-06 Impact factor: 9.139